论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
免疫抑制性糖蛋白(Glycodelin)作为接受 EGFR 酪氨酸激酶抑制剂治疗的晚期肺腺癌脑转移患者的生物标志物
Authors Ni Z, Zhang L, Zheng J, Su X, Zhang S
Received 24 May 2019
Accepted for publication 3 August 2019
Published 6 November 2019 Volume 2019:11 Pages 9421—9425
DOI https://doi.org/10.2147/CMAR.S216971
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Eileen O'Reilly
Objective: Brain metastasis (BM) is a serious complication of advanced lung adenocarcinoma and is a prominent factor leading to lung cancer mortality. In this study, the expression of the glycodelin protein was analyzed in EGFR-mutant tyrosine kinase inhibitor-sensitive advanced lung adenocarcinoma.
Methods: This study features a retrospective analysis of 74 advanced lung adenocarcinoma patients treated at our hospital from January 2010 to December 2017. The expressions of glycodelin were assessed by standard immunohistochemistry and correlated with clinicopathological factors and overall survival (OS) outcomes.
Results: Patients with advanced lung adenocarcinoma with glycodelin overexpression were prone to BM (P < 0.05), and exhibited significantly shortened OS (11.8 months vs 20.4 months, P < 0.05). Multivariate regression analysis showed that overexpression of glycodelin and brain metastases were independent factors affecting the prognosis of advanced lung adenocarcinoma (P < 0.05).
Conclusion: The overexpression of glycodelin is closely related to the presence of brain metastasis in lung adenocarcinoma, and can be used as an auxiliary diagnostic index for prognosis of advanced lung adenocarcinoma.
Keywords: glycodelin, advanced lung adenocarcinoma, brain metastasis, prognosis
